title: [Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
abstract: Glioblastoma is a brain tumor with poor prognosis in the therapy of which operation, postoperative temozolomide sensitized radiochemotherapy followed by temozolomide monotherapy offer the best chances. Administration of temozolomide is also recommended in relapse if the patient is naïve to this treatment. In recurrent or progressive glioblastoma following the above therapy, several biological therapeutic agents were tested, out of which the angiogenesis inhibitor bevacizumab has been approved by FDA (and similar authority of several other countries). Bevacizumab monotherapy resulted in objective tumor response in 28.2%, the median of progression-free survival was 4.2 (2.9-5.8) months, the median of overall survival was 9.2 (8.2-10.7) months. When combined with irinotecan, these results were 37.8%, 5.6 (4.4-6.2) and 8.7 (7.8-10.9) months, respectively. Adverse events were known from the use of bevacizumab in other indications, symptoms affecting the central nervous system were mild, i.e. the therapy proved to be not only effective but safe as well. Reduction of edema provided further advantage. In Hungary the product is available for "off-label" use only through a fairness request process.
authors.affiliation: Megyei Onkológiai Központ, Pándy Kálmán Megyei Kórház, Gyula, Hungary. dr.piko.bela@gmail.com
authors.forename: Béla
authors.initials: B
authors.lastname: Pikó
authors.forename: Ali
authors.initials: A
authors.lastname: Bassam
authors.forename: Krisztina Agnes
authors.initials: KA
authors.lastname: Nagy
authors.forename: Enikõ
authors.initials: E
authors.lastname: Török
authors.forename: Rita
authors.initials: R
authors.lastname: Vághy
authors.forename: Rózsa
authors.initials: R
authors.lastname: Vargáné Tamás
authors.forename: Klára
authors.initials: K
authors.lastname: Puskásné Szatmári
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018450:Disease Progression; D017277:Drug Approval; D005060:Europe; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D006814:Hungary; D000077146:Irinotecan; D008279:Magnetic Resonance Imaging; D056687:Off-Label Use; D012008:Recurrence; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D000068258:Bevacizumab; D000077146:Irinotecan; D003606:Dacarbazine; D002166:Camptothecin; D000077204:Temozolomide